Content area

|
|

Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer

Forfatter(e)
Charlotte Suppli Ulrik1, 2 1) Lungemedicinsk Afdeling, Hvidovre Hospital 2) Det Sundhedsvidenskabelige Fakultet, Københavns Universitet Ugeskr Læger 2014;176:V02140088
Reference: 
Ugeskr Læger 2014;176:V02140088
Blad nummer: 
Sidetal: 
2-6
The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients
Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Patricia Duch | 18/11
1 Kommentar
af Pål Ledaal | 18/11
3 kommentarer
af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer